Achieve life sciences, inc. (ACHV)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating Activities:
Net loss

-3,320

-3,194

-3,673

-3,624

-5,904

-3,637

-3,240

-2,788

-3,022

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-2,997

-3,269

-5,843

-3,690

-6,889

-3,707

-1,724

-4,550

-6,010

-4,517

-5,681

-4,908

-7,015

-8,636

-6,678

-10,054

-8,420

-6,697

-4,103

-5,920

-4,215

-6,860

-19,777

-4,471

12,620

-3,045

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization [note 3]

61

-

62

65

65

-

66

68

86

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on warrants [note 7 and note 11[e]]

-

-

-

-

-

-

-

-

-

-39

7

-66

-52

-118

-621

533

-667

-1,731

-131

430

-465

-973

-2,874

-615

721

-334

-539

-901

-1,434

-1,937

-2,308

-1,644

1,430

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

37

93

40

45

47

56

66

62

70

46

58

55

55

55

65

62

56

44

29

28

24

19

-

-

-

19

Stock-based compensation [note 6 [c] and note 6 [d]]

302

284

310

317

290

266

210

197

181

196

-271

212

211

396

-134

919

468

388

712

712

516

892

952

1,016

1,000

344

887

855

748

565

581

709

320

322

312

283

271

Restructuring gain [note 8]

-

-

-

-

-

-

-

-

-

-

-

9

98

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Interest receivable

-

-

-

-

-

-

-

-

-

-

-

0

-32

-4

-11

-6

-58

63

-28

5

-42

94

19

-166

-52

-77

-5

-21

-6

-180

35

100

9

-

-

-

-

Gain on warrants [notes 4 and 5]

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,581

1,688

-2,128

Amounts receivable

-8

-

-

-

-

-

-

-

-

-155

401

4

-241

320

-149

74

219

1

-136

-1,410

-4,117

849

-124

-3,659

-47

-1,265

3,483

1,283

4,442

83

147

82

-47

36

-511

150

124

Prepaid expenses and other assets

190

402

-87

-422

-88

555

221

-216

-217

-248

2,244

-458

-189

-693

350

-313

-401

387

-712

-1,684

842

-298

-327

666

-3,985

2,993

-879

230

-370

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,285

869

-

1,956

428

-1,519

Accounts payable

-675

285

-133

13

550

-314

207

-169

207

-282

2,288

-126

-1,762

1,078

484

-33

-751

-436

1,477

-686

916

-1,490

221

418

784

100

-91

-1,069

-130

-

-

-

-

-

-

-

-

Accrued liabilities other

-130

-8

82

-203

-199

-7

-211

434

94

-1,062

156

231

-1,510

1,840

-20

-287

268

1,830

-143

-60

-1,849

134

-1,236

208

1,257

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical liabilities

184

-

-

-

887

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical liabilities

-

-

-

-

-

-

-

8

-103

-

3,527

-292

-3,073

-3,699

-589

-747

-1,516

-220

-510

813

-3,797

-

-

-

-

409

2,061

3,240

1,853

-

-

-

-

-

-

-

-

Accrued compensation

-697

-

352

367

-680

-

321

158

134

-

-751

44

22

-1,234

94

584

-523

-343

358

521

-602

224

128

77

-801

348

220

444

-848

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-3

29

-27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

32

0

-61

0

0

0

-63

-

-

-

-

-

-

-

-

-

-

-

-

Excess lease liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-194

-203

-199

-194

-189

-176

-173

-167

-164

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-340

-

-178

477

273

Excess lease liability [note 6]

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

203

185

-

84

-228

247

Lease obligation [note 7]

4

-

-

-

-14

-

-

-

-

20

-85

19

19

18

17

2

14

13

14

-3

-124

17

16

21

30

6

5

13

-3

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

30

0

0

0

10

-

-

-

-

-

-

-

-

Net cash used in operating activities

-4,461

-3,414

-3,072

-3,841

-4,889

-3,541

-2,981

-1,868

-2,233

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,935

-13,678

-7,383

-4,440

-6,192

-5,588

-4,043

Financing Activities:
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs

-

-

-

-

-

-

-

175

1,105

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred collaboration revenue [note 3]

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2,099

-2,941

-

-

-

-

-

-

-

-

-

-

-

-

-9,145

-6,227

-1,963

-936

-765

-831

-1,174

-581

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-2,531

-8,995

-6,979

-7,263

-6,354

-9,087

-10,685

-8,632

16,660

-6,444

-6,944

-5,760

-2,912

-1,692

-7,538

-10,231

-7,467

-10,691

-

-

-

-

-

-

-

-

Taxes paid related to net share settlement of equity awards

-

-

-

-

-

-

-

-

-

-17

0

3

19

-

-

-

-

0

0

0

52

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-1

5

2,379

5,014

4,942

24,169

1,426

20,917

3,096

-1,071

14,167

5,064

164

51

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

112

2

-

-

-

91

Issuance of common shares, net of share issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-53,777

-

-

-

-

Net cash used in financing activities

-47

-

-

-

-

5,010

846

12,796

1,105

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

346

112

53,779

6

122

0

91

Investing Activities:
Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,550

18,785

11,280

26,130

10,011

32,592

41,710

14,557

16,368

15,608

28,614

Proceeds from sale of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

-

-

3,254

23,651

-55,865

17,262

35,171

16,088

Proceeds from maturities of investments

-

-

-

-

-

-

-

-

-

-

-

759

9,475

12,800

13,500

2,999

17,859

4,000

9,647

5,001

3,011

48

1

9,087

15,758

8,279

5,966

29,503

19,627

-

-

-

-

-

-

-

-

Purchase of property and equipment

2

1

0

-2

54

-

-

-

-

-

-

0

1

-

-

-

-

70

36

60

205

2

13

60

7

19

9

115

110

-

-

-

-

3

8

36

32

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-3

-19

-

-

-

-

14

14,416

3,213

-52

13

19,170

6,034

30

0

0

0

10

-

-

-

-

-

-

-

-

Proceeds on disposal of assets

-

-

-

-

-

0

0

0

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of investments

-

0

0

5

20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

-

0

0

2,350

2,764

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

760

9,469

10,414

8,482

-1,978

-6,310

2,504

-11,306

2,848

3,877

-14,121

-5,076

8,863

15,700

9,179

4,407

7,603

11,237

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-2

-1

0

2,347

2,690

-3,709

-1,390

-36

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,071

-29,427

-18,059

17,213

886

19,527

-12,558

Effect of exchange rate changes on cash

2

1

1

-2

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-1

-

5

0

2

-

-

-

-

-

-

-

-

-

-

-1

-1

2

25

-15

-3

-

38

-17

-2

15

31

-61

-25

Net increase (decrease) in cash, cash equivalents and restricted cash

-4,508

9,289

-3,071

3,126

-2,195

-2,240

-3,525

10,893

-1,119

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-1,774

457

3,433

1,219

-8,332

-15,397

-8,167

-5,524

22,723

-2,619

-21,053

8,336

11,984

14,037

1,643

-5,799

121

553

6,713

-2,480

-43,010

28,335

12,794

-5,153

13,878

-16,535

Property and equipment acquired under lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

-

-

-

-

-1

0

19

71

December 2019 Registered Direct Offering [Member]
Costs relating to registered direct offering and purchase agreement

34

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-